Alvogen Launches First Generic Exelon Patch in the US
Alvogen recently announced it has launched the first generic equivalent of Exelon patch (rivastigmine transdermal system) in the US. The product will be marketed by Alvogen in three strengths (4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours) with Alvogen being the first filer for the 13.3 mg/24 hours strength, making it eligible for 180 days of marketing exclusivity. Novartis’ Exelon patch delivered sales of approximately $400 million in the US during 2014, according to IMS data.
“This exclusive launch is another significant step in Alvogen’s journey. We have demonstrated our ability to move with speed to develop and market high-quality generic medicines to our customers and the patients they treat. We are delighted to be able to bring a more affordable alternative to the market,” said Robert Wessman, Chairman and CEO of Alvogen. “We have developed over 60 pipeline ANDAs for the US market, of which 28 have first-to-file or first-to-market potential. This is a clear indication of our progress and our ambition to become one of the leading players in the global pharmaceuticals market.”
Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC), and biosimilar products for patients around the world. The company has commercial operations in 35 countries with 2,300 employees and operates four manufacturing and development hubs in the US, Romania, Korea, and Taiwan. North America is Alvogen’s single largest market and other key markets include: South Korea, West Balkan, Poland, Romania, Bulgaria, Hungary, Taiwan, Thailand, Ukraine, Russia, Japan, and China. For more information, visit www.alvogen.com.
Total Page Views: 1965
